SLC5A2 and hydrops fetalis: The meta-analysis of Gager et al. (1) confirmed the consistent efficacy of SGLT2 inhibitors on the composite HF outcome (i.e., a composite of HHF/CVM) in various HF subgroups defined by several important factors, such as baseline diabetes status, type of SGLT2 inhibitors, and baseline level of eGFR.